Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 289 to 294 of 294 entries
Sorted by: Best Match Show Resources per page
Can Recent Health Crises Create Opportunities for Deprescribing?.

The Senior care pharmacist

Turner JP.
PMID: 34452650
Sr Care Pharm. 2021 Sep 01;36(9):422-425. doi: 10.4140/TCP.n.2021.422.

No abstract available.

Cite
Turner JP. Can Recent Health Crises Create Opportunities for Deprescribing?. Sr Care Pharm. 2021;36(9):422-425doi: 10.4140/TCP.n.2021.422.
Turner, J. P. (2021). Can Recent Health Crises Create Opportunities for Deprescribing?. The Senior care pharmacist, 36(9), 422-425. https://doi.org/10.4140/TCP.n.2021.422
Turner, Justin P. "Can Recent Health Crises Create Opportunities for Deprescribing?." The Senior care pharmacist vol. 36,9 (2021): 422-425. doi: https://doi.org/10.4140/TCP.n.2021.422
Turner JP. Can Recent Health Crises Create Opportunities for Deprescribing?. Sr Care Pharm. 2021 Sep 01;36(9):422-425. doi: 10.4140/TCP.n.2021.422. PMID: 34452650.
Copy Download .nbib Format: NLM
Variability in reporting of key outcome predictors in acute myocardial infarction cardiogenic shock trials.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions

Tyler JM, Brown C, Jentzer JC, Baran DA, van Diepen S, Kapur NK, Garberich RF, Garcia S, Sharkey SW, Henry TD.
PMID: 33871159
Catheter Cardiovasc Interv. 2022 Jan 01;99(1):19-26. doi: 10.1002/ccd.29710. Epub 2021 Apr 19.

BACKGROUND: Among acute myocardial infarction patients with cardiogenic shock (AMICS), a number of key variables predict mortality, including cardiac arrest (CA) and shock classification as proposed by Society for Cardiovascular Angiography and Intervention (SCAI). Given this prognostic importance, we...

Cite
Tyler JM, Brown C, Jentzer JC, et al. Variability in reporting of key outcome predictors in acute myocardial infarction cardiogenic shock trials. Catheter Cardiovasc Interv. 2021;99(1):19-26doi: 10.1002/ccd.29710.
Tyler, J. M., Brown, C., Jentzer, J. C., Baran, D. A., van Diepen, S., Kapur, N. K., Garberich, R. F., Garcia, S., Sharkey, S. W., & Henry, T. D. (2022). Variability in reporting of key outcome predictors in acute myocardial infarction cardiogenic shock trials. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 99(1), 19-26. https://doi.org/10.1002/ccd.29710
Tyler, Jeffrey M, et al. "Variability in reporting of key outcome predictors in acute myocardial infarction cardiogenic shock trials." Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions vol. 99,1 (2022): 19-26. doi: https://doi.org/10.1002/ccd.29710
Tyler JM, Brown C, Jentzer JC, Baran DA, van Diepen S, Kapur NK, Garberich RF, Garcia S, Sharkey SW, Henry TD. Variability in reporting of key outcome predictors in acute myocardial infarction cardiogenic shock trials. Catheter Cardiovasc Interv. 2022 Jan 01;99(1):19-26. doi: 10.1002/ccd.29710. Epub 2021 Apr 19. PMID: 33871159.
Copy Download .nbib Format: NLM
Natural killer cells and cytotoxic T lymphocytes are required to clear solid tumor in a patient-derived xenograft.

JCI insight

Le DT, Huynh TR, Burt B, Van Buren G, Abeynaike SA, Zalfa C, Nikzad R, Kheradmand F, Tyner JJ, Paust S.
PMID: 34081628
JCI Insight. 2021 Jul 08;6(13). doi: 10.1172/jci.insight.140116.

Existing patient-derived xenograft (PDX) mouse models of solid tumors lack a fully tumor donor-matched, syngeneic, and functional immune system. We developed a model that overcomes these limitations by engrafting lymphopenic recipient mice with a fresh, undisrupted piece of solid...

Cite
Le DT, Huynh TR, Burt B, et al. Natural killer cells and cytotoxic T lymphocytes are required to clear solid tumor in a patient-derived xenograft. JCI Insight. 2021;6(13)doi: 10.1172/jci.insight.140116.
Le, D. T., Huynh, T. R., Burt, B., Van Buren, G., Abeynaike, S. A., Zalfa, C., Nikzad, R., Kheradmand, F., Tyner, J. J., & Paust, S. (2021). Natural killer cells and cytotoxic T lymphocytes are required to clear solid tumor in a patient-derived xenograft. JCI insight, 6(13), . https://doi.org/10.1172/jci.insight.140116
Le, Duy Tri, et al. "Natural killer cells and cytotoxic T lymphocytes are required to clear solid tumor in a patient-derived xenograft." JCI insight vol. 6,13 (2021). doi: https://doi.org/10.1172/jci.insight.140116
Le DT, Huynh TR, Burt B, Van Buren G, Abeynaike SA, Zalfa C, Nikzad R, Kheradmand F, Tyner JJ, Paust S. Natural killer cells and cytotoxic T lymphocytes are required to clear solid tumor in a patient-derived xenograft. JCI Insight. 2021 Jul 08;6(13). doi: 10.1172/jci.insight.140116. PMID: 34081628; PMCID: PMC8410059.
Copy Download .nbib Format: NLM
Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing.

JAMA neurology

Sechi E, Buciuc M, Pittock SJ, Chen JJ, Fryer JP, Jenkins SM, Budhram A, Weinshenker BG, Lopez-Chiriboga AS, Tillema JM, McKeon A, Mills JR, Tobin WO, Flanagan EP.
PMID: 33900394
JAMA Neurol. 2021 Jun 01;78(6):741-746. doi: 10.1001/jamaneurol.2021.0912.

IMPORTANCE: Myelin oligodendrocyte glycoprotein-IgG1-associated disorder (MOGAD) is a distinct central nervous system-demyelinating disease. Positive results on MOG-IgG1 testing by live cell-based assays can confirm a MOGAD diagnosis, but false-positive results may occur.OBJECTIVE: To determine the positive predictive value (PPV)...

Cite
Sechi E, Buciuc M, Pittock SJ, et al. Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. JAMA Neurol. 2021;78(6):741-746doi: 10.1001/jamaneurol.2021.0912.
Sechi, E., Buciuc, M., Pittock, S. J., Chen, J. J., Fryer, J. P., Jenkins, S. M., Budhram, A., Weinshenker, B. G., Lopez-Chiriboga, A. S., Tillema, J. M., McKeon, A., Mills, J. R., Tobin, W. O., & Flanagan, E. P. (2021). Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. JAMA neurology, 78(6), 741-746. https://doi.org/10.1001/jamaneurol.2021.0912
Sechi, Elia, et al. "Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing." JAMA neurology vol. 78,6 (2021): 741-746. doi: https://doi.org/10.1001/jamaneurol.2021.0912
Sechi E, Buciuc M, Pittock SJ, Chen JJ, Fryer JP, Jenkins SM, Budhram A, Weinshenker BG, Lopez-Chiriboga AS, Tillema JM, McKeon A, Mills JR, Tobin WO, Flanagan EP. Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. JAMA Neurol. 2021 Jun 01;78(6):741-746. doi: 10.1001/jamaneurol.2021.0912. PMID: 33900394; PMCID: PMC8077043.
Copy Download .nbib Format: NLM
Neurofascin-155 Immunoglobulin Subtypes: Clinicopathologic Associations and Neurologic Outcomes.

Neurology

Shelly S, Klein CJ, Dyck PJB, Paul P, Mauermann ML, Berini SE, Howe B, Fryer JP, Basal E, Bakri HM, Laughlin RS, McKeon A, Pittock SJ, Mills J, Dubey D.
PMID: 34635556
Neurology. 2021 Dec 14;97(24):e2392-e2403. doi: 10.1212/WNL.0000000000012932. Epub 2021 Oct 11.

BACKGROUND AND OBJECTIVE: Multiple studies highlighting the diagnostic utility of neurofascin-155 (NF155)-immunoglobulin G4 (IgG4) in chronic demyelinating inflammatory polyradiculoneuropathy (CIDP) have been published. However, few studies comprehensively address the long-term outcomes or clinical utility of NF155-immunoglobulin M (IgM) or...

Cite
Shelly S, Klein CJ, Dyck PJB, et al. Neurofascin-155 Immunoglobulin Subtypes: Clinicopathologic Associations and Neurologic Outcomes. Neurology. 2021;97(24):e2392-e2403doi: 10.1212/WNL.0000000000012932.
Shelly, S., Klein, C. J., Dyck, P. J. B., Paul, P., Mauermann, M. L., Berini, S. E., Howe, B., Fryer, J. P., Basal, E., Bakri, H. M., Laughlin, R. S., McKeon, A., Pittock, S. J., Mills, J., & Dubey, D. (2021). Neurofascin-155 Immunoglobulin Subtypes: Clinicopathologic Associations and Neurologic Outcomes. Neurology, 97(24), e2392-e2403. https://doi.org/10.1212/WNL.0000000000012932
Shelly, Shahar, et al. "Neurofascin-155 Immunoglobulin Subtypes: Clinicopathologic Associations and Neurologic Outcomes." Neurology vol. 97,24 (2021): e2392-e2403. doi: https://doi.org/10.1212/WNL.0000000000012932
Shelly S, Klein CJ, Dyck PJB, Paul P, Mauermann ML, Berini SE, Howe B, Fryer JP, Basal E, Bakri HM, Laughlin RS, McKeon A, Pittock SJ, Mills J, Dubey D. Neurofascin-155 Immunoglobulin Subtypes: Clinicopathologic Associations and Neurologic Outcomes. Neurology. 2021 Dec 14;97(24):e2392-e2403. doi: 10.1212/WNL.0000000000012932. Epub 2021 Oct 11. PMID: 34635556; PMCID: PMC8673722.
Copy Download .nbib Format: NLM
Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia.

NPJ precision oncology

White BS, Khan SA, Mason MJ, Ammad-Ud-Din M, Potdar S, Malani D, Kuusanmäki H, Druker BJ, Heckman C, Kallioniemi O, Kurtz SE, Porkka K, Tognon CE, Tyner JW, Aittokallio T, Wennerberg K, Guinney J.
PMID: 34302041
NPJ Precis Oncol. 2021 Jul 23;5(1):71. doi: 10.1038/s41698-021-00209-9.

The FDA recently approved eight targeted therapies for acute myeloid leukemia (AML), including the BCL-2 inhibitor venetoclax. Maximizing efficacy of these treatments requires refining patient selection. To this end, we analyzed two recent AML studies profiling the gene expression...

Cite
White BS, Khan SA, Mason MJ, et al. Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. NPJ Precis Oncol. 2021;5(1):71doi: 10.1038/s41698-021-00209-9.
White, B. S., Khan, S. A., Mason, M. J., Ammad-Ud-Din, M., Potdar, S., Malani, D., Kuusanmäki, H., Druker, B. J., Heckman, C., Kallioniemi, O., Kurtz, S. E., Porkka, K., Tognon, C. E., Tyner, J. W., Aittokallio, T., Wennerberg, K., & Guinney, J. (2021). Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. NPJ precision oncology, 5(1), 71. https://doi.org/10.1038/s41698-021-00209-9
White, Brian S, et al. "Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia." NPJ precision oncology vol. 5,1 (2021): 71. doi: https://doi.org/10.1038/s41698-021-00209-9
White BS, Khan SA, Mason MJ, Ammad-Ud-Din M, Potdar S, Malani D, Kuusanmäki H, Druker BJ, Heckman C, Kallioniemi O, Kurtz SE, Porkka K, Tognon CE, Tyner JW, Aittokallio T, Wennerberg K, Guinney J. Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. NPJ Precis Oncol. 2021 Jul 23;5(1):71. doi: 10.1038/s41698-021-00209-9. PMID: 34302041; PMCID: PMC8302655.
Copy Download .nbib Format: NLM
Showing 289 to 294 of 294 entries